Affimed N.V. (NASDAQ:AFMD) has scheduled a conference call for 23rd June 2020 at 8:30 AM Eastern Time to announce its 1Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website edge.media-server.com/mmc/p/n5vo3v39
To participate on the live call, please dial +1-646-741-3167 Toll Free, (United States) or +44 (0) 2071 928338 Toll Number, with passcode : 8594214
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The companys products include AFM24, an innate cell-engaging bispecific antibody that treats patients suffering of EGFR expressing solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.
